OpenEvidence is expanding its footprint in New York City through a partnership with NYU Langone Health, adding another marquee institution to an existing concentration of partnerships across the city's academic medical centers.
OpenEvidence's AI-powered clinical evidence platform is embedded directly into NYU Langone's Epic electronic health record (EHR) workflows. NYU Langone has more than 12 million outpatient visits annually, 421,000 emergency department visits, seven inpatient locations and more than 400 outpatient locations. The integration will span NYU Langone's hospitals, ambulatory network and the Family Health Centers and will also reach physicians who are training at NYU Grossman School of Medicine and NYU Grossman Long Island School of Medicine.
The system has more than 6,000 physicians and faculty, 2,000+ residents and fellows and 54,000 employees.
“At NYU Langone, we are committed to working with OpenEvidence to make the latest technology available to our clinicians in a safe and practical environment at scale,” said Nader Mherabi, executive vice president and vice dean, chief digital and information officer at NYU Langone Health said in a statement.
OpenEvidence developed an AI-powered medical search engine and a generative AI chatbot exclusively for doctors, which summarizes and simplifies evidence-based medical information. It has grown to become one of the most widely used medical AI and CDS tools in the industry. The company says it's "patient-aware clinical intelligence" uses agentic clinical AI to integrate details of the patient record with the evidence from the medical literature.
NYU Langone clinicians will be able to ask complex clinical questions in natural language and receive answers grounded in peer-reviewed medical literature and read against the patient’s own clinical record, all without leaving their Epic workflow, according to OpenEvidence executives.
“NYU Langone cares for New Yorkers at a scale few institutions in the country can match, and it does so while setting the standard of care across specialties,” Daniel Nadler, founder and CEO of OpenEvidence, said in a statement. “New York has always been where American medicine goes to prove itself at scale. Putting OpenEvidence inside the chart at NYU Langone means the world's medical literature is now in the room for every one of the twelve million visits this system supports each year.”
OpenEvidence has already amassed a large following among individual clinicians, with the company saying roughly two-thirds of U.S. physicians use its platform. As of October, there were 1.2 million medical license-verified U.S. clinicians, including physicians and nurses, using OpenEvidence, Nadler told Fierce Healthcare. Verified U.S. clinicians consulted OpenEvidence 45 million times in October alone, he said.
AI has integrated deeply into specialized medicine as well. There are 300 million physical specialist visits, such as seeing a cardiologist or oncologist, in the U.S. per year. Nadler said OpenEvidence handles about one query from a medical specialist for every patient visit to a medical specialist in America.
OpenEvidence already has substantial clinician usage, and the company is now pushing deeper into health systems.
The agreement with NYU Langone builds on OpenEvidence's broader reach in New York. The company already has an enterprise rollout across NewYork-Presbyterian's 10 hospitals and nearly 350 care sites, a health-system-wide deployment at Mount Sinai, and a specialized precision oncology partnership with Memorial Sloan Kettering Cancer Center. It also has partnerships with leading New York City medical schools around clinical training and research.
A recent large-scale study examined OpenEvidence’s rapid adoption and how clinicians are using AI in the clinic. Nearly 1 million U.S. clinicians submitted 271 million AI-enabled clinical queries through OpenEvidence's platform from January 2024 to June 2026, according to a paper published in JAMA. More than half of the users in the sample (556,200) were physicians, according to researchers from Harvard Medical School and Brigham and Women’s Hospital. These physicians submitted an average of 37 queries per month of use. Early-career physicians and those in oncology, hematology, internal medicine and family medicine submitted a higher-than-average share of queries, according to the study.
The study found that most of the queries were related to clinical decision-making (51.9%), particularly treatment and management. Diagnosis accounted for 13.9% of queries.
“Two key takeaways are that an enormous number of physicians are using AI for clinical care and that they are often using it in areas where they don’t have specific expertise,” said corresponding author Anupam Jena, the Joseph P. Newhouse Professor of Health Care Policy in the Blavatnik Institute at HMS and HMS professor of medicine at Massachusetts General Hospital.
“Everyone appreciates the huge potential for AI to change how medicine is practiced, but right now we have limited information on how many doctors are using it, what they are using it for, and how it’s impacting patients,” Jena said. The JAMA study tackles the first two of those questions, the researchers noted.
The study also found that monthly active OpenEvidence users increased from 355 in January 2024 to 703,265 in June 2026. Queries per active user increased substantially, from 18 per month to 39.5, and month-to-month retention reached roughly 90% in 2026. By June, 92.5% of active users were returning users rather than brief adopters, according to the study.